Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivmecillinam as oral step-down treatment for Escherichia coli febrile urinary tract infection versus standard of care
2023-503447-33-00Phase 2Authorised
- Sponsor
- Uppsala University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in urinary tract infection (UTI) comparing Oral pivmecillinam step-down with Standard-of-care oral step-down therapy (2 arms). Primary endpoint: Clinical response at test of cure (primary endpoint). Planned start Oct 2025; status: authorised.
02
Drugs
pivmecillinam
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2023-503447-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503447-33-00.